^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Asparagine depleter

    Related drugs:
    2d
    Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Truxima (rituximab-abbs) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neulasta (pegfilgrastim) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim)
    3d
    A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma (ChiCTR2600117389)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    decitabine • Epidaza (chidamide) • Oncaspar liquid (pegaspargase)
    6d
    AML16: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    sorafenib • azacitidine • etoposide IV • decitabine • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neupogen (filgrastim) • dexrazoxane
    2ms
    CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Asparlas (calaspargase pegol-mknl)
    2ms
    Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Mayo Clinic | Initiation date: Nov 2025 --> Feb 2026
    Trial initiation date
    |
    Asparlas (calaspargase pegol-mknl)
    3ms
    Efficacy and safety of DAPT regimen (dexamethasone, azacitidine, pegaspargase, tislelizumab) for NK/T cell lymphoma (ChiCTR2500109853)
    P2, N=50, Recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • azacitidine • dexamethasone • Oncaspar liquid (pegaspargase)
    3ms
    Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Mayo Clinic
    New trial
    |
    Asparlas (calaspargase pegol-mknl)
    3ms
    CASPER: Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, OHSU Knight Cancer Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Cotellic (cobimetinib) • Asparlas (calaspargase pegol-mknl)
    3ms
    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=53, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Mar 2029 | Trial primary completion date: Apr 2028 --> Mar 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    4ms
    SPARK-ALL: Calaspargase Pegol in Adults With ALL (clinicaltrials.gov)
    P2/3, N=122, Active, not recruiting, Institut de Recherches Internationales Servier | Trial primary completion date: Feb 2026 --> Mar 2025
    Trial primary completion date
    |
    Asparlas (calaspargase pegol-mknl)
    4ms
    Asparagine Synthetase promoter hypermethylation is required, but not sufficient, for sensitivity to Asparlas in patient-derived models of hepatocellular carcinoma. (PubMed, Eur J Pharmacol)
    However, when a panel of patient derived xenograft models representing a range of pASNSmet levels was tested we found that high pASNSmet levels were required but not necessarily sufficient to confer sensitivity to treatment with Asparlas. Collectively, these results are in support of ASNS promoter hypermethylation as a targetable phenotype but indicate that pASNSmet alone is not a viable biomarker of this phenotype, and that significant advancements in our understanding of the underlying biology may be required before asparaginase-depleting therapy can be successfully implemented clinically in HCC.
    Journal
    |
    ASNS (Asparagine synthetase)
    |
    Asparlas (calaspargase pegol-mknl)
    4ms
    A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) (clinicaltrials.gov)
    P2, N=22, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • decitabine • Asparlas (calaspargase pegol-mknl)